Co-Authors
This is a "connection" page, showing publications co-authored by Shibo Jiang and Xinling Wang.
Connection Strength
3.048
-
Pan-coronavirus fusion inhibitors as the hope for today and tomorrow. Protein Cell. 2021 02; 12(2):84-88.
Score: 0.923
-
Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases. Int J Mol Sci. 2020 May 28; 21(11).
Score: 0.884
-
Supercoiling Structure-Based Design of a Trimeric Coiled-Coil Peptide with High Potency against HIV-1 and Human ß-Coronavirus Infection. J Med Chem. 2022 02 24; 65(4):2809-2819.
Score: 0.236
-
RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduct Target Ther. 2020 11 27; 5(1):282.
Score: 0.229
-
Retraction Note to: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion. Cell Mol Immunol. 2020 08; 17(8):894.
Score: 0.224
-
The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin. Signal Transduct Target Ther. 2020 06 12; 5(1):92.
Score: 0.222
-
RETRACTED ARTICLE: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion. Cell Mol Immunol. 2020 04 07.
Score: 0.219
-
Engineered trimeric ACE2 binds viral spike protein and locks it in "Three-up" conformation to potently inhibit SARS-CoV-2 infection. Cell Res. 2021 01; 31(1):98-100.
Score: 0.057
-
Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection. Virol Sin. 2020 06; 35(3):340-343.
Score: 0.055